

Robert Steinmetz, MD

2439 Care Dr. • Tallahassee, FL 32308
Phone: 850.942.6700 • Fax: 850.942.5735 • E-Mail: Robert.steinmetz@svaretina.com

EDUCATION

- B.A. Magna Cum Laude, Luther College, Decorah, Iowa 08/1974-05/1978**
- M.D. University of Iowa College of Medicine, Iowa City, Iowa 08/1978-05/1982**

POSTGRADUATE TRAINING

- **The Gundersen Medical Foundation, LaCrosse Lutheran Hospital, LaCrosse, Wisconsin**
Rotating Internship **1982 - 1983**
- **The University of Utah, Salt Lake City, Utah**
Ocular Pathology Fellowship with David J. Apple, M.D. **07/1983- 10/1983**
- **Pacific Presbyterian Medical Center, San Francisco, California**
Residency in Ophthalmology **11/1983- 10/1986**
- **The Jules Stein Eye Institute, UCLA, Los Angeles, California**
Fellowship in Vitreous and Retinal Diseases and Surgery **07/1987- 06/1989**
- **Moorfields Eye Hospital, London, England**
Medical Retina Fellow to Alan C. Bird, M.D., FRCS **07/1989- 02/1991**

TEACHING APPOINTMENTS

- **University of Essen Eye Hospital, Essen, Germany**
Oberarzt, (senior staff member) Director: Prof. Dr. A. Wessing **05/1991- 02/1992**
- **University of Bonn Eye Hospital, Bonn, Germany**
Oberarzt, Director: Prof. Dr. M. Spitznas **03/1992-12/1992**
- **Florida State University, School of Medicine**
Clerkship Faculty **11/2003-present**

EMPLOYMENT POST TRAINING

- **Southern Vitreoretinal Associates, PPL 1993 - present**

CERTIFICATION AND LICENSURE

- **American Board of Ophthalmology 1990**
Licensed Physician in the states of Florida, Georgia, and Alabama

HOSPITAL AFFILIATIONS

- **Tallahassee Memorial Hospital, Tallahassee, FL**
- **Phoebe Putney Memorial Hospital, Albany, GA**

HONORARY SOCIETIES

- **American Academy of Ophthalmology (fellow) 1990**

- **American Society of Retinal Surgeons (Vitreous Society)** 1997
- **The Retina Society** 2005

ASSOCIATIONS

- **American Medical Association** 1993
- **Florida Society of Ophthalmology** 1998

AWARDS

- **Abe Meyer Fellowship** 1987 - 1989

PUBLICATIONS

Peer-reviewed Journal Articles:

Apple DJ, Craythorn JM, Reidy JJ, Steinmetz RL, Brady SE, and Bohart WA. Malignant transformation of an optic nerve melanocytoma. *Can J Ophthalmol* 1984;119:320.

Mamalis N, Apple DJ, Notz RG, Steinmetz RL, Loftfield K, and Olson RJ. Phacoanaphylactic endophthalmitis following ECCE and IOL implantation. (Guest editorial) *Am Intraocular Implant Soc J* 1984;10:423-424.

Apple DJ, Mamalis N, Steinmetz RL, Loftfield K, Crandall AS, and Olson RJ. Phacoanaphylactic endophthalmitis associated with extracapsular cataract extraction and posterior chamber intraocular lens. *Arch Ophthalmol* 1984;102:1528-1532.

Reidy JJ, Apple DJ, Steinmetz RL, Craythorn JM, Loftfield K, Gieser SC, and Brady SE. Melanocytoma: Nomenclature, pathogenesis, natural history, and treatment. *Surv Ophthalmol* 1985;29:319-327.

Ai E. and Steinmetz RL. Aging and the retina. *Geriatr Ophthalmol* 1987; 3:8-11.

Steinmetz RL, Kreiger AE, and Sidikaro Y. Previtreal space gas sequestration during pneumatic retinopathy. (Letter) *Am J Ophthalmol* 1989;107:191-192.

Steinmetz RL, Masket S, and Sidikaro Y. The successful removal of a subretinal cysticercus by pars plana vitrectomy. *Retina* 1989; 9:276-280.

Steinmetz RL, Straatsma BR, and Rubin ML. Posterior vitreous cyst. *Am J Ophthalmol* 1990;109:295-297.

Steinmetz RL, Straatsma BR, Rubin ML. Posterior vitreous cyst. (Correspondence). *Am J Ophthalmol* 1990; 110:326.

Steinmetz RL, Garner A, Maguire JI, and Bird AC. Histopathology of incipient fundus flavimaculatus. *Ophthalmol* 1991; 98:953-956.

Steinmetz RL, Fitzke FW, and Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. *Retina* 1991; 11:412-415.

Steinmetz RL, Polkinghorne PC, Fitzke FW, Kemp CM, and Bird AC. Abnormal dark adaptation and rhodopsin kinetics in Sorsby's fundus dystrophy. *Invest Ophthalmol Vis Sci* 1992; 33:1633-1636.

Boeker T, Feng C, and Steinmetz RL. Refractive error and choroidal perfusion characteristics in patients with age-related macular degeneration and subretinal neovascularization. *German J Ophthalmol* 1993; 2:10-13.

Brockmeyer NH, Hengge UR, Mertins L, Malessa R, Steinmetz R, Gooss M. Foscarnet treatment in various cytomegalovirus infections. *Int J Clin Pharmacol Ther Toxicol* 1993;31(4):204-7.

Sheraidah G, Steinmetz RL, Maguire JI, Pauleikhoff D, Marshall J., and Bird AC. Correlation between lipids extracted from Bruch's membrane and age. *Ophthalmol* 1993;100:47-51.

Steinmetz RL, Haimovici R, Jubb C, Fitzke FW, and Bird AC. Symptomatic abnormalities of dark adaptation in patients with age-related Bruch's membrane change. *Brit J Ophthalmol* 1993;77:549-554.

Koch FHJ, Schmidt H, Monks T, Blumenroeder S, Moeller G, Haller A, and Steinmetz RL. Multiport illumination system (MIS) for vitreous surgery: A quantitative analysis of its retinal irradiance and spectral properties. *Am J Ophthalmol* 1993;116:489-496.

Koch FHJ, Schmidt H, Monks T, Blumenroeder S, Moeller G, Haller A, and Steinmetz RL. Multiport illumination system (MIS) for vitreous surgery. (Correspondence) *Am J Ophthalmol* 1994; 117:682-683.

Boeker T and Steinmetz RL. Hyperopia and choroidal neovascularization. (Correspondence) *Ophthalmol* 1994; 101:972.

Steinmetz RL, and Brooks HL Jr. Diode laser photocoagulation to the ridge and avascular retina in threshold retinopathy of prematurity. *Retina* 2002; 22:48-52.

Steinmetz RL, Grizzard WS, and Hammer MH. Vitrectomy for diabetic traction retinal detachment using the multiport illumination system. *Ophthalmol* 2002;109:2303-2307.

Steinmetz RL and Brooks HL Jr. Diode laser photocoagulation to the ridge and avascular retina in threshold retinopathy of prematurity. (Correspondence) *Retina* 2003;23:127.

Steinmetz RL, Brooks HL Jr, and Newell CK. Management of posteriorly dislocated posterior chamber intraocular lenses with vitrectomy and pars plana removal. *Retina* 2004;24:556-559.

HL Brooks Jr MD, CK Newell MD, RL Steinmetz MD, D Watson BS, CRA, CDA, MS Segal MD, JK Harrison PhD, EW Scott PhD and MB Grant MD. Vitreous levels of VEGF and SDF-1 in patients with diabetic retinopathy and cystoid macular edema. *Arch Ophthalmol* 2004; 122:1801-1807.

Steinmetz RL. Management of posteriorly dislocated posterior chamber intraocular lenses with vitrectomy and pars plana removal. (Correspondence) *Retina* 2005;25:385-386

Newell CK, Steinmetz RL, Brooks HL Jr. Chronic postoperative endophthalmitis caused by *Bipolaris Australiensis*. *Retina* 2006;26:109-110.

Charkoudian LD, Kaiser GM, Steinmetz RL, Srivastava SK. Acute retinal necrosis after herpes Zoster vaccination. *Arch Ophthalmology*. 2011; 129:1495-1497.

Steinmetz RL, Vyas S, Ashmore E, Brooks HL Jr. Acute-Onset Postoperative Endophthalmitis in silicone oil-filled eyes managed with intravitreal antibiotics alone. *Journal of VitreoRetinal Diseases*. 2018; 2:107-110.

Steinmetz RL, Steinmetz CZ, Reyes-Capo DP, Brooks, HL, Sengillo JD, Miller D, Flynn HW, Jr. Nutritionally variant Streptococci causing endophthalmitis associated with intravitreal anti-vascular endothelial growth factor injection. *American Journal of Ophthalmology*. Case Reports. <https://doi.org/10.1016/j.ajoc.2021.101019>

Contributions to Textbook:

Apple D.J., and Rabb M.J. Third Revised Edition: Clinical Applications of Ocular Pathology: A text and stereoatlas. C.V. Mosby Co.: St. Louis, MO 1984.

PAPER PRESENTATIONS AND LECTURES

Acute Retinal Necrosis Syndrome: The UCLA Experience. The Barkan Association Alumni Day. San Francisco, CA 1988.

Pneumatic Retinopexy: An Analysis of a Series. Steinmetz RL, Hanscomb TA, Bundy K, and Diddie KR. The Retina Society. Philadelphia, PA 1988.

Uveodermatologic Syndrome in Dogs: A Model of Vogt-Koyanagi-Harada Syndrome. Boldy KL, Furlong RC, Holland GN, Steinmetz RL, and Foos RY. The Combined Meeting of the American Uveitis and Veterinary Ophthalmologic Societies. Las Vegas, NV 1988.

The Long-Term Effects of Acetazolamide in a Patient with Retinitis Pigmentosa. Steinmetz RL, Chen JC, Fitzke FW, and Bird AC. The Nineteenth Annual Cambridge Ophthalmological Symposium. Cambridge, England 1989.

Prolonged Dark Adaptation in Patients with Age-Related Macular Degeneration. Steinmetz RL, Walker D, Fitzke FW, and Bird AC.

- The ARVO Annual Meeting. Sarasota, FL 1991. Invest Ophthalmol Vis Sci (suppl) 32 (1991):711.
- The 4th Annual Meeting of the German Retina Society. Tubingen, Germany 1991.

Determinants of Fluorescence of Deposits in Bruch's Membrane in Age-Related Maculopathy. Pauleikhoff D, Steinmetz RL, Marshall J, Sheraidah G, Wessing A, and Bird AC. The ARVO Annual Meeting. Sarasota, FL 1991. Invest Ophthalmol Vis Sci (suppl) 32 (1991):711.

Laser Photocoagulation to the Ridge in Threshold Retinopathy of Prematurity. Steinmetz RL and Brooks HL Jr. The American Academy of Ophthalmology Annual Meeting. Atlanta, GA 1995.

Using the Multiport Illumination System (MIS) with Wide-Angle Viewing Systems. The Florida Society of Ophthalmology Annual Meeting. Lake Buena Vista, FL 1998.

Management of Dislocated Posterior Chamber Intraocular Lenses. The Florida Society of Ophthalmology Annual Meeting. Amelia Island, FL 2000.

Case Presentation: Undiagnosed Choroidopathy. The Florida Society of Ophthalmology Annual Meeting. Palm Beach, FL 2001.

Repair of Retinal Detachment and Proliferative Vitreoretinopathy With and Without Internal Limiting Membrane Peeling. Brooks HL, Steinmetz RL, Newell CK. Retina Congress, (the combined meeting of the Vitreous Society and the Retina Society). San Francisco, CA 2002.

Vitreous Levels of VEGF and SDF-1 in Patients with Diabetic Retinopathy. Brooks HL, Newell CK, Steinmetz RL, Fortin J, Caballero S, Grant MB. The ARVO Annual Meeting. Ft. Lauderdale, FL 2003. Invest Ophthalmol Vis Sci (suppl) (2003):178.

A Clear View of Diabetic Retinopathy. Update on Diabetes and Vascular Disease. Annual Conference for the Capital Medical Society. Tallahassee, FL 2004.

Macular Pucker Diagnosis and Management.
Georgia Optometric Association Annual Meeting. Destin, FL 2005.

Pars Plana Removal of Dislocated Posterior Chamber Intraocular Lenses.
The Florida Society of Ophthalmology Annual Meeting. Boca Raton, FL 2005.

Intravitreal Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration, 2.5 mg vs 1.25 mg. Brooks HL, Ashmore ED, Barker DL, Steinmetz RL, Newell CK. The ARVO Annual Meeting. Ft. Lauderdale, FL May 2006.

Endophthalmitis in a Silicone Oil-filled Eye Following Retinal Detachment Repair Managed with Intravitreal Antibiotics. Steinmetz RL.

- Nantucket Retina Society, Nantucket, MA, 2017
- (Interesting case conference) Retina Society, Boston, MA 2017

POSTER PRESENTATIONS

Uveodermatologic Syndrome in Dogs: A Model of Vogt-Koyanagi-Harada Syndrome. Furlong RC, Boldy KL, Holland GN, Steinmetz RL, and Foos RY. The ARVO Annual Meeting. Sarasota, FL 1989. Invest Ophthalmol Vis Sci (suppl) 30 (1990):86.

Abnormal Dark Adaptation and Rhodopsin Kinetics in Sorsby's Fundus Dystrophy. Steinmetz RL, Polkinghorne PC, Fitzke FW, Kemp CM, and Bird AC. The ARVO Annual Meeting. Sarasota, FL 1990. Invest Ophthalmol Vis Sci (suppl) 31 (1990):413.

Vitrectomy for Diabetic Traction Retinal Detachment Using the Multiport Illumination System. Steinmetz, RL, Grizzard WS, Hammer MH. The American Academy of Ophthalmology Annual Meeting. Dallas, TX 2000.

Assessment of Triamcinolone Treatment for Neovascular Glaucoma. Brooks HL, Caballero S, Newell CK, Steinmetz RL, Watson D, Grant MB. The ARVO Annual Meeting. Ft. Lauderdale, FL 2004. Invest Ophthalmol Vis Sci.

SCIENTIFIC EXHIBIT AND VIDEO PRESENTATIONS

Age-Related Macular Degeneration: Clinical Course, Histopathology, and Treatment. Ai E, Singerman LJ, Green WR, Coonan P, Steinmetz RL. The American Academy of Ophthalmology Annual Meeting. San Francisco, CA 1985.

Advantages of the Multiport Illumination System (MIS) in Vitreous Surgery for Proliferative Diabetic Retinopathy. Koch FHJ, Steinmetz RL, Boeker TH, and Spitznas M. The Annual Meeting of the Bavarian Ophthalmologists. Regensburg, Germany 1992. The Vitreous Society Annual Meeting. Laguna Nigel, California 1992.

The Vitreoretinal Frontier Meeting. Dallas, Texas 1992.

INSTRUCTIONAL COURSES

The Third Annual Ocular Oncology Course. The Jules Stein Eye Institute. Steinmetz, R.L. Choroidal Hemangioma: Diagnosis and Management. Los Angeles, CA 1988.

The 27th Annual Essen Education for Ophthalmologists. Wessing A., Steinmetz RL, and Pauleikhoff D. Indications for Fluorescein Angiography. Essen, Germany 1992.

CLINICAL TRIALS

Principal Investigator:

Hoffman-La Roche. STAIRWAY, Phase 2. RO6867461 for wet AMD	2016
Genentech. LUCERNE, Phase 3. Faricimab for wet AMD	2018
Graybug Vision. GRAYBUG, Phase 1/2. Extended release Sunitinib intravitreal depot	2019
Genetech. AVONELLE-X, Open-label Extension. Faricimab injections in patients with nAMD	2021

Sub-Investigator:

Miravant Medical Technologies. TAP, Phase 3. Classic CNV in wet AMD	1998
Alcon Research. Anecortave Acetate, Phase 3. Anecortave in wet AMD	2003
Genentech. ANCHOR, Phase 3. Lucentis vs PDT for wet AMD.	2003
Alcon Research. AART, Phase 3. Anecortave Acetate CNV prevention in AMD.	2004
Genentech. HORIZON, Phase 3. Extension study of Lucentis in wet AMD.	2006
Genentech. BRAVO, Phase 3. Lucentis for ME in BRVO.	2007
Genentech. CRUISE, Phase 3. Lucentis for ME in CRVO.	2007
Novartis Pharmaceutical. Fingolimod, Phase 2. Macular Edema in MS	2007
OpkoHealth, Inc. COBALT, Phase 3. Bevasiranib following Lucentis in wet AMD.	2008
Ophthotech Corp. Fovista, Phase 3. Fovista in wet AMD	2015
Allergan. BEACON, Phase 2. Brimonidine geographic atrophy in AMD.	2015
Novartis. Alcon, Phase 2. RTH258 versus aflibercept in wet AMD.	2015
Hoffman-LaRoche. CHROMA, Phase 3. Lampalizumab for GA in AMD.	2015
Regeneron. ONYX, Phase 2. Nesvacmab and aflibercept in wet AMD	2016
Hoffman-LaRoche. BOULEVARD, Phase 3. RO6867461 in DME	2016
DigiSight Technologies, Inc. CLEAR, Paxos Check up Mobile App	2016
Regeneron. PANORAMA, Phase 3. Aflibercept in Diabetic Retinopathy	2016
Opthea. OPT-302, Phase 2b. with ranibizumab in wet AMD	2017

Clearside Biomedical. TOPAZ, Phase 3. Triamcinolone acetonide in RVO	2017
F. Hoffman-La Roche. YOSEMITE, Phase 3. Faricimab and aflibercept in DME	2018
F. Hoffman-La Roche. ARCHWAY, Phase 3. Port Delivery with ranibizumab for wet AMD	2018
F. Hoffmann-La Roche. PAGODA, Phase 3. Port delivery with Ranibizumab for DME	2019
Hemera Biosciences. HEMERA, Phase 2. AAVCAGsCD59 for advanced dry	2019
Regeneron Pharmaceuticals. CANDELA, Phase 2. High dose aflibercept for neovascular AMD	2019
Genentech. GALLEGO, Phase 2. FHTR2163 for GA secondary to AMD	2020
Iveric bio. GATHER2, Phase 3. Zimura for GA secondary to dry AMD	2020
Gemini Therapeutics. GEMINI, Phase 2. Repeat intravitreal injections of GEM103 for GA secondary to dry AMD	2020
NGM Biopharmaceuticals. CATALINA, Phase 2. Intravitreal NGM621 for GA secondary to AMD	2020
Apellis Pharmaceuticals. DERBY, Phase 3. APL-2 for GA secondary to AMD	2020
F. Hoffman-La Roche. BP41670, Phase 1. RO7250284 multiple ascending doses & port delivery for neovascular AMD	2020
Regeneron Pharmaceuticals. PULSAR, Phase 3. Aflibercept in neovascular AMD	2020

Kodiak Sciences Inc. GLIMMER, Phase 3. intravitreal KS1-301 compared to aflibercept for visual impairment secondary to treatment-naïve DME	2020
Aerie Pharmaceuticals Inc. AERIE, Phase 1. Safety of AR-13503 sustained implant release for DME	2020
F. Hoffmann-La Roche. PAVILION Phase 3, Port delivery system with ranibizumab	2020
Novartis. CONDOR, Phase 3. brolucizumab compared to photocoagulation laser in PDR	2020
Kodiak Sciences Inc. BEACON, Phase 3. Safety of KSI-301 compared to aflibercept in Macular Edema secondary to RVO	2020
F. Hoffman-La Roche. BALATON, Phase 3. faricimab for macular edema secondary to branch RVO	2020
F. Hoffman-La Roche. COMINO, Phase 3. faricimab for macular edema secondary to central retinal or hemiretinal vein occlusion	2020
F. Hoffman-La Roche. RHONE-X, Extension. faricimab with DME	2020
F. Hoffman-La Roche. PORTAL, Extension. port delivery of ranibizumab for neovascular AMD	2020
Genetech. GALLEGOLE, Open-label Extension. FHTR2163 injections for GA Secondary to AMD	2020
REGENXBIO. ATMOSPHERE, Phase 2b/3. RGX-314 Gene Therapy with nAMD	2021
Opthea. COAST, Phase 3. OPT-302 in combination with Aflibercept with nAMD	2021
Apellis Pharmaceuticals. GALE, Open-label Extension. Pegcetacoplan for GA secondary to AMD	2021

Kodiak Sciences Inc. GLOW, Phase 3. Intravitreal KSI-301 for
Moderately Severe to Severe NPDR

2021

PRESS MENTIONS

Macular Degeneration Affects Eyes Tallahassee Democrat 1/5/1998

<https://nwspprs.com/3bwt>

Treatment Tested For Macular Degeneration Tallahassee Democrat 1/4/1999

<https://nwspprs.com/3b9wv>

Drug Restores Sight in Some AMD Patients Tallahassee Democrat 7/8/2006

<https://www.newspapers.com/image/249860146>